Li Jun, Zhang Han, Sun Peng, Gu Feng, Liu Zhe-Li
Department of Ophthalmology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China.
Int J Ophthalmol. 2013 Apr 18;6(2):169-73. doi: 10.3980/j.issn.2222-3959.2013.02.12. Print 2013.
To compare the clinical efficacy of intravitreal injections of bevacizumab and ranibizumab for treating Chinese patients with neovascular age-related macular degeneration (AMD).
Among 60 Chinese patients with exudative AMD (60 eyes), 28 received intravitreal bevacizumab injections (1.25mg) and 32 received intravitreal ranibizumab injections (0.5mg), once a month for 3 months and were followed for a total of 6 months. Monthly optical coherence tomography (OCT) was used to determine whether the patients received additional treatments during the follow-up. We compared the baseline and 6-month follow-up values of mean best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in both groups of patients. We also compared the occurrence of adverse events.
At the 6-month follow-up, the mean BCVA (logMAR) of the bevacizumab and ranibizumab treatment groups improved from the baseline measurements of 0.72±0.23 and 0.73±0.22 to 0.47±0.14 and 0.45±0.20, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. As evaluated by OCT, CRT decreased from 366.71±34.72µm and 352±36.9µm at baseline to 250.86±41.51µm and 243.22±41.38µm in the bevacizumab and ranibizumab groups, respectively (P<0.05 for both groups). However, the change was not significantly different between the two groups. There were no severe local adverse reactions or systemic adverse events.
Intravitreal bevacizumab and ranibizumab have equivalent effects on BCVA and CRT and appeare safe over the short-term.
比较玻璃体内注射贝伐单抗和雷珠单抗治疗中国新生血管性年龄相关性黄斑变性（AMD）患者的临床疗效。
在60例中国渗出性AMD患者（60只眼）中，28例接受玻璃体内注射贝伐单抗（1.25mg），32例接受玻璃体内注射雷珠单抗（0.5mg），每月1次，共3个月，随访6个月。每月使用光学相干断层扫描（OCT）确定患者在随访期间是否接受额外治疗。比较两组患者的平均最佳矫正视力（BCVA）和视网膜中央厚度（CRT）的基线值和6个月随访值。我们还比较了不良事件的发生率。
在6个月随访时，贝伐单抗和雷珠单抗治疗组的平均BCVA（logMAR）分别从基线测量值0.72±0.23和0.73±0.22改善至0.47±0.14和0.45±0.20（两组均P<0.05）。然而，两组之间的变化无显著差异。通过OCT评估，贝伐单抗组和雷珠单抗组的CRT分别从基线时的366.71±34.72µm和352±36.9µm降至250.86±41.51µm和243.22±41.38µm（两组均P<0.05）。然而，两组之间的变化无显著差异。没有严重的局部不良反应或全身不良事件。
玻璃体内注射贝伐单抗和雷珠单抗对BCVA和CRT的作用相当，且短期内似乎是安全的。
